Fracture risk is heightened in patients with both type 1 diabetes (T1D) and type 2 diabetes (T2D). Although bone mineral density by dual-energy X-ray absorptiometry is decreased in T1D, it is paradoxically increased with T2D. To predict fracture risk, the Fracture Risk Assessment Tool (FRAX) can be used in diabetes patients, albeit with refinement. Skeletal abnormalities in diabetes include alterations in microarchitecture in T1D and T2D as well as compromised impact microindentation in T2D. Changes in bone microvasculature, advanced glycation end product accumulation, and bone formation may underlie these findings. When fractures occur in T1D and T2D, consequences are worse than in nondiabetic patients with regard to both morbidity and mortality. With regard to treatment, antiresorptive osteoporosis therapies appear to be effective in the setting of diabetes.
Introduction
Diabetes mellitus is a metabolic disease that vastly affects public health. It impacts over 415 million individuals and this number is expected to double by 2040. 1 The major complications of diabetes are well known, namely microvascular issues including retinopathy and nephropathy. More recently, epidemiologic data have shown that the skeleton is also a target tissue in diabetes. Individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) have an increased risk of a fracture, with the consequences of fractures being more harmful than in nondiabetics. This article reviews the mechanisms for increased fracture risk in diabetes, how to predict the increased risk, and the evidence regarding use of osteoporosis therapies in patients with diabetes.
Type 1 diabetes fracture epidemiology
Skeletal health in T1D is gaining clinical relevance because of the increased life expectancy of T1D patients. 2 Individuals with T1D can now expect to live to an age where fractures are of potential concern. Robust evidence is present for an escalated risk of hip fractures in T1D; a meta-analysis of seven studies showed a relative risk of hip fracture of 3.8 (2.0−7.0). 3 This was confirmed in a subsequent study that additionally demonstrated that the higher hip fracture risk commences at age 40 and persists throughout older ages. 4 In addition to hip fractures, fracture risk at all sites was increased as compared with nondiabetics at all ages. 4 
Type 1 diabetes bone mineral density
The increased fracture risk in T1D can be partially attributable to a moderate reduction in bone mineral density (BMD). A meta-analysis demonstrated that BMD Z-scores at the spine and hip in T1D patients were reduced to −0.22 and −0.37, respectively. 5 With that degree of BMD reduction, the calculated theoretical increase in hip fracture risk was 1.42. 5 However, since the actual observed increase is approximately threefold higher, 3 this gap suggests that factors other than BMD, known as doi: 10.1111/nyas.13463 bone quality, likely contribute to the greater risk of a hip fracture with T1D.
Type 2 diabetes fracture epidemiology
T2D prevalence is particularly high in older adults. Data from NHANES show that a quarter of older adults in the United States have T2D; 6 importantly, this is the same age group in which concerns are greatest with regard to fracture risk. 7 There is consistent evidence of increased fracture risk in T2D, although the risk is not as high as in T1D. A metaanalysis that included eight studies revealed a 40% increased risk of hip fractures in T2D after adjusting for age. 5 The hip fracture risk was 70% in a different meta-analysis of 12 studies that adjusted for larger body size and increased BMD. 8 Data examining sites other than the hip indicate that overall fracture risk is also elevated in T2D. A report from the Women's Health Initiative Observational Cohort demonstrated increases in fractures at multiple sites, including the proximal humerus, foot, ankle, and clinical spine in T2D women, in addition to confirming a 40% increased hip fracture risk. 9 More recently, race and ethnicity were shown to relate to diabetic fracture risk. NHANES data looking at all fracture types in T2D showed an increased risk of 22% in non-Hispanic whites, of 87% in nonHispanic blacks, and a doubling of risk in Mexican Americans. 10 These data suggest that the relationship between fracture risk and diabetes is strongest in non-white individuals in the United States. With regard to fracture risk with prediabetes, there does not seem to be a continuum in the progression from euglycemia to impaired glucose tolerance to frank diabetes. 11 Using a 2-h glucose tolerance test, individuals with impaired glucose tolerance in fact had protection from fractures as compared with a normoglycemic reference group. 11 Moreover, newly diagnosed diabetic patients, on the basis of the 2-h glucose test, had a similar fracture risk as the normoglycemic group, suggesting that duration of diabetes increases risk. It was only in the established diabetes patients that fracture risk (non-spine) was increased, by approximately 70%. Diabetes-related risk factors are common in T2D patients who sustain a fracture. In addition to longer duration of T2D, suboptimal control of glucose also increases fracture risk. 9, [12] [13] [14] [15] Use of insulin treatment is additionally associated with an increased risk of fractures, although it is unclear if this is a direct effect of the medication itself or if insulin use is a proxy for more advanced disease. [16] [17] [18] [19] Diabetic complications such as retinopathy increase fracture risk, 17 as does use of certain medications, such as thiazolidinediones.
What accounts for the higher fracture risk in T1D and T2D? Falls Falls in diabetes likely explain a portion of the increased diabetes fracture risk. In a meta-analysis examining the risk of falls in patients with T2D, a 20% (HR 1.19 (95% CI: 1.1-1.3)) increased risk of falls was observed with T2D patients as compared with nondiabetics. 20 Falls are specifically increased in patients on insulin. 21 Data on whether falls are increased in T1D are not available. Nevertheless, falls do not completely explain the increased diabetes fracture risk. In studies modeling the relationship between diabetes and fracture, even after adjustment for falls there is an independent association between diabetes and fracture. 9, 11, 18, 22 Some of this risk might be captured by insulin use. In a recent report (N = 429,313) it was shown that T2D patients regardless of medical regimen are more likely to fall than nondiabetics, but hip fractures were only increased in insulin users (HR 1.24 (95% CI: 1.16 1.32)). 23 This suggests that a mechanism that affects bone strength (e.g., insulin use or diabetes complications) in addition to falls likely plays a role in the increased fracture risk.
Bone strength
Bone strength is measured clinically as areal BMD by dual-energy X-ray absorptiometry (DXA). In T1D, as noted above, the reduced BMD is a contributing factor to fracture risk. In contrast, BMD in T2D is typically higher than in individuals without diabetes. A meta-analysis of 15 observational studies showed that BMD in T2D was increased as compared with nondiabetics, with a difference of 0.04 g/cm 2 (95% CI: 0.02-0.05) at the femoral neck, 0.06 g/cm 2 (95% CI: 0.04-0.08) at the hip, and 0.06 g/cm 2 (95% CI: 0.04-0.07) at the spine. 24 For a given BMD, T2D patients have an increased fracture risk. 25 An analysis of patients followed in several longitudinal cohorts (SOF, Osteoporotic Fractures in Men (MrOS), and Health ABC) showed that while lower BMD predicted fracture risk in patients with T2D, for a given T-score fracture risk was shifted upward and thus underestimated (Fig. 1) . 25 For example, the risk of a hip fracture risk in a woman with diabetes and a DXA T-score at the femoral neck of −2.0 is similar to the risk in a woman at the same age without diabetes who has a −2.6 DXA femoral neck T-score. Of note, although BMD is cross-sectionally higher, more rapid bone loss occurs in white women with T2D with a greater loss of femoral neck BMD (−0.32%/year; 95% CI: −0.61 to −0.02) observed over 4 years. 26 Although this is seemingly inconsistent with the higher BMD levels observed in T2D, it might be due to higher BMI levels that earlier on in the course of diabetes could be dominant over later bone loss.
The Fracture Risk Assessment Tool (FRAX) has been evaluated with regard to fracture prediction in T2D. The tool is based on individual patient models that integrate the risks associated with clinical risk factors as well as BMD at the femoral neck. However, fracture risk in patients with T2D is underestimated by FRAX. 25, 27 Several methods have been proposed to capture the effect of T2D despite its absence as an input variable in FRAX. One such method is to substitute rheumatoid arthritis in the calculation as a proxy for T2D, because the effect seems to be very similar to that of T2D. 28 Another method is to use the recently validated trabecular bone score (TBS) adjustment for FRAX. 29 TBS is a texture analysis derived from the anterior-posterior DXA that looks for the degree of heterogeneity in the bone, with a lower (more heterogeneous) score being predictive of fracture. 30 In diabetes, TBS is reduced, despite better BMD measures, and predicts fracture better than DXA, 31 suggesting that there may be a bone deficit in diabetes that is approximately captured by TBS. Thus, the FRAX fracture prediction in a T2D patient can be refined by adding rheumatoid arthritis or adjusting for TBS. Alternatively, it has been suggested to lower the femoral neck T-score by 0.5 SD. 
Bone quality in diabetes
In addition to BMD, bone strength is composed of aspects of bone quality, including microarchitecture, geometry, and material properties. Use of tools other than DXA has shed light on how these bone properties might be altered in diabetic individuals.
Microarchitecture
High-resolution peripheral quantitative computed tomography (HRpQCT) has permitted detailed noninvasive assessment of trabecular and cortical microarchitectural properties in diabetic patients. A number of studies suggest that cortical deficits are present in T1D and T2D, while trabecular microarchitecture is compromised in T1D only. A study of T1D patients using HRpQCT demonstrated that cortical thickness and volumetric BMD were decreased, with trabecular number also decreased in the presence of diabetic microvascular disease. 32 Another HRpQCT study reported that cortical porosity was 124% greater in T2D postmenopausal women (n = 19) as compared with 19 nondiabetic controls. 33 A smaller (26%) increase in cortical porosity was also observed in 22 T2D African-American women as compared with controls. 34 A preliminary analysis from the Framingham cohort similarly showed increased porosity in T2D along with reduced cortical volumetric BMD without any compromise to trabecular bone. 35 A difference in cortical porosity within T2D patients with and without fractures (n = 20/group) has also been observed. 36 Cortical porosity was increased in the fracture group at the distal tibia by 87.9% and at the distal radius by 4.7-fold ( Figure 2 ). 36 Nonetheless, uncertainties exist about the cortical porosity findings. The absolute differences in overall cortical porosity between individuals with and without T2D are <2.5% and may not significantly influence bone strength. 33, 34 In a recent study, distal radial cortical porosity was in fact lower in 99 women with T2D than in 954 nondiabetic women (1.5% versus 2.0%, P = 0.001). 37 Other studies have also reported no difference in porosity between T2D and controls. 36, 38, 39 Thus, it remains uncertain whether there is an association between porosity and diabetes. It should also be considered that misplacement of the threshold-based segmentation endosteal contour 40 might be more likely in T2D because of the increased trabecular bone volume fraction that is present. 33, 36, 38, 41 Such misplacement could theoretically misclassify trabecularization of the subendocortical cortex as cortical porosity.
Microindentation
Recently, impact microindentation has opened the possibility of directly assessing the mechanical characteristics of cortical bone in living individuals. 37, 42, 43 This technique measures the distance that a metal probe can enter the tibia for a given applied force. The measurement, Bone Material Strength index (BMSi), is considered to reflect the ability of bone to resist microcrack generation and propagation. 44 In a study of human bone samples, the indentation distance increase correlated inversely with crack growth toughness (r = −0.90).
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In postmenopausal women with T2D, BMSi was reduced as compared with controls despite no difference in BMD, 38 suggesting a deficit in diabetic bone material. A relationship between diabetes and bone material was further supported in that study by a negative correlation between HbA1c levels over the prior 10 years with BMSi. 38 In a similar study of postmenopausal women with and without T2D, BMSi was reduced in the diabetic women and correlated inversely with duration of diabetes. 39 Reduced BMSi was also found in T2D as compared with controls in a larger, population-based study 37 These studies suggest that impaired bone material is present in T2D and might relate to the duration and extent of hyperglycemia exposure. Microindentation has not been tested in T1D.
Gene expression in T2D rodents
There are numerous rodent models of T2D with various gene expressions. One model of severe T2D is the db/db mouse, a strain of C57BL/KsJ mice that has an autosomal recessive mutation of the gene db, which codes for the leptin receptor. 45 Obesity, insulin resistance, and hyperglycemia are key features of db/db mice, 45 with fasting hyperglycemia reaching 400 mg/dL. 46 Skeletal abnormalities in db/db mice include lower femoral cortical thickness and area, 47 as well as multiple trabecular and cortical microarchitectural abnormalities. 48 Mechanically, as compared with controls, db/db mice have decreased stiffness and femoral failure load. 48 The Zucker diabetic fatty (ZDF) is a rat model of T2D that, similar to the db/db mouse, results from a leptin receptor mutation. 49 The ZDF rat has obesity at all stages, with early insulin resistance, followed by hyperglycemia and later decreased insulin secretion, along with features of diabetic neuropathy and nephropathy. 50 Skeletal abnormalities in the ZDF rat include decreased femoral length and diameter as compared with controls. 51 Although CT measures show no difference in ZDF rats from controls at 7 weeks, 52 subsequent decreases in BMD at the hind limbs and spine develop. 53 With both the db/db mouse and ZDF rat models, it is important to note that leptin gene or receptor mutations can independently alter BMD. Other rodent models of T2D, without this potential confounder of the effects of diabetes on bone, are available. 54 Nevertheless, most of the rodent models of T2D are limited with regard to studies of bone strength in T2D because the onset of diabetes usually precedes skeletal maturation, and bone mass is decreased, in contrast to the clinical adult scenario of increased BMD. 54 
Mechanisms for deficits in diabetic bone
Microvasculature A significant portion of the cardiac output goes to bone and provides the skeleton with oxygen and nutrients while removing metabolic waste. Vascular complications that are known to develop in diabetes, such as calcification and defective vasodilation, might also develop in the bone and perhaps impair bone properties. Interestingly, patients with atherosclerotic vascular disease also have increased cortical porosity, 55 suggesting that diabetic changes in bone structure might be related to poor perfusion. There is indirect evidence that microvascular complications 4, 56 are risk factors for bone deficits in T1D and T2D. In T1D, lower BMD measures are associated with microvascular complications. 57 Two studies have also suggested that bone microarchitecture might be associated with microvascular disease in T1D. In T1D patients with retinopathy, MRI of the proximal tibia showed that bone volume/total volume was lower. 58 Similarly, patients with T1D and retinopathy displayed lower trabecular and cortical volumetric BMD as well as trabecular number and cortical thickness by HRpQCT than T1D patients without retinopathy. 32 In contrast, the T1D patients without microvascular complications had bone microarchitecture that was no different from controls. 32 In T2D, patients with microvascular complications (retinopathy, nephropathy, or neuropathy) had decreased cortical thickness and volumetric BMD and, at the radius, greater cortical porosity as compared with controls. 59 Trabecular bone was unaffected and, as in T1D, there was no difference between T2D patients who did not have microvascular complications and controls. 59 As data are limited, 56 further investigation is necessary to determine whether microvasculature is indeed related to microarchitectural deficits in diabetes.
Advanced glycation end products
Advanced glycation end products (AGEs) are formed when free-floating sugars interact with exposed amino acid residues on collagen, resulting in a reversible Amadori intermediate that ultimately undergoes oxidation to form irreversible AGEs. [60] [61] [62] [63] [64] These compounds accumulate in patients with diabetes 63 and create nonenzymatic cross-links within type 1 collagen. 65, 66 AGEs reduce the material and biomechanical properties of bone by stiffening the bone collagen and reducing bone strength independent of BMD by DXA. 65, 66 In murine studies, AGE accumulation accelerates in the setting of diabetes and correlates with multiple measures of bone strength. 67 A recent clinical study looked at a measure of AGEs by skin autofluorescence and found an inverse correlation with BMSi by impact microindentation (Fig. 3) . 39 Cadaveric studies in 28 women directly measured AGEs in bone, demonstrating that higher AGE content in bone was associated with worse bone material strength (AGE content and BMSi: r = −0.613, P < 0.001). 68 These data suggest that AGEs in bone and collagen matrix contribute to impaired material properties in bone. Further support for this concept comes from a study in which urinary levels of the AGE pentosidine predicted subsequent fractures in patients with T2D. 69 Thus, indirect evidence suggests that AGEs may in part be responsible for reduced bone strength in diabetes.
Hyperglycemia and reduced bone formation
Hyperglycemia appears to have a direct effect on bone cells, especially on osteoblasts and osteocytes, leading to reduced bone formation. [70] [71] [72] A number of cellular mechanisms for this effect have been described. In vitro, hyperglycemia suppresses bone formation by increasing osteocyte expression of sclerostin. 73 Chronic hyperglycemia and inflammation also decrease VEGF-A expression by osteoblasts that diminishes the proangiogenic potential of the bone microenvironment, leading to impaired fracture healing. 74, 75 Streptozotocin-induced diabetic mice were recently shown to have decreased angiogenesis and chondrocyte VEGF-A expression after fracture induction, abnormalities that were reversible by specific inhibition of TNF-␣. 76 In that study, hyperglycemia also impaired angiogenesis by decreasing the ability of microvascular endothelial cells to respond to proliferative factors and instead triggering their apoptosis. 76 Numerous clinical studies have demonstrated biochemical evidence for reduced bone formation and resorption in diabetes. [77] [78] [79] [80] This is unexpected given the higher fracture risk in T2D because in broader populations, such as postmenopausal osteoporosis, higher bone turnover is associated with fracture risk. 81 Importantly, reduced bone turnover, usually a protective factor, might not protect as well against fracture risk in T2D because it allows accumulation of AGEs in bone collagen. Of note, caution should be used with interpretation of serum C-telopeptide (CTX) levels in diabetes. As diabetes is associated with a reduction in enzymatic cross-links, reliance on serum CTX levels could theoretically lead to an underestimation of actual bone resorption. Histomorphometry data are scant. In T1D, a histomorphometry study of iliac crest bone biopsies found no difference in bone formation versus matched controls, although this study only included T1D patients without any microvascular complications. 82 In that study, in the T1D patients with fractures, the presence of the AGE pentosidine in the bone together with a higher degree of mineralization was associated with reduced bone flexibility. 83 Whether there is a greater reduction in bone formation as compared with bone resorption in diabetes is uncertain. In a histomorphometry study of T2D, indices of bone formation (bone formation rate, mineralizing surface, and osteoblast numbers/bone surface) were reduced (Figure 4) , although only five T2D and four controls were assessed. 84 Resorption indices (eroded surfaces and osteoclast numbers/bone surface) were the same in T2D and controls. Thus, bone formation appears to be reduced in T2D patients, while bone resorption might be intact, although the data are very limited.
Bone turnover might also be affected by insulin signaling. Osteoblasts express insulin receptors and animal data suggest that greater insulin signaling correlates with bone formation, while insulin resistance reduces bone remodeling. 85, 86 It is conceivable that bone develops insulin resistance that might lead to decreased bone turnover. 
Diabetes and mesenchymal stem cell differentiation
The marrow stem cell (MSC) niche, which promotes the development of precursor osteoblast cells, 87 is compromised in diabetes, possibly as a result of microvascular disease or other factors. In a study of streptozotocin-induced diabetic rats, MSCs were isolated and analyzed for their ability to proliferate and differentiate in a fibroblastic colony-forming unit assay. 88 The size and number of osteoblastic colonies (alkaline phosphatase positive) were significantly reduced in the diabetic as compared with nondiabetic rats. 88 Twelve weeks after the induction of diabetes, there was a 50% decrease in bone-committed MSCs, along with a significant loss of trabecular bone. 88 Similarly, in a mouse model of T2D, the expression of mouse skeletal precursor cells was altered by high serum concentrations of TNF-␣ that led to compromised fracture healing. 89 Mesenchymal skeletal progenitors are linked to insulin sensitivity through the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-␥ , with ligand activation of PPAR-␥ favoring differentiation of mesenchymal stem cells into adipocytes rather than osteoblasts. 90 Indeed, the same posttranslational modifications of the PPAR-␥ protein that control energy metabolism and insulin sensitivity similarly regulate bone remodeling. 91 PPAR-␥ controls differentiation of cellular components of bone turnover; it suppresses osteoblast differentiation by shunting MSCs away from the osteoblastic and to the adipocytic lineage. 92, 93 PPAR-␥ also enhances recruitment of hematopoietic stem cells, directing them to the osteoclast lineage.
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Sclerostin Sclerostin is an osteocyte-secreted protein that inhibits bone formation by binding to LRP5 or 6 and thus blocking anabolic Wnt/␤-catenin signaling. 94 A number of studies indicate that sclerostin levels are increased in T2D patients 95, 96 along with suppressed ␤-catenin levels. 97 Higher sclerostin levels in T2D have been associated with an increased risk of vertebral fractures independent of lumbar spine BMD. 98, 99 Interestingly, sclerostin levels in T1D patients are not increased. 96, 100 Whether sclerostin could be a biomarker to predict increased fracture risk in T2D patients requires further investigation.
Insulin deficiency
In T1D, lack of endogenous insulin leads to reduced IGF-1, an important factor for bone formation. Lower BMD and bone size in children with T1D are associated with a decrease in anabolic insulin effects on bone 101 and alterations in growth hormone and IGF-1 levels. 102 IGF-1 stimulatory effects on osteoblasts in vivo are blunted by increased levels of AGEs and increased glucose concentrations might induce osteoblast resistance to the actions of IGF-1.
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Alterations in marrow fat Increased bone marrow adiposity in the vertebrae is associated with greater fracture risk. 104, 105 In addition, the composition of bone marrow adipose tissue is altered with low bone mass, with a decrease in unsaturated levels. 106 Both the amount and composition of bone marrow fat appear to be altered in diabetes. In the MrOS study, diabetic men had higher bone marrow fat as compared with nondiabetic men. 107 With regard to bone marrow fat composition, T2D postmenopausal women with fragility fractures had higher saturated bone marrow fat and lower unsaturated bone marrow fat as compared with nondiabetic controls and to T2D without fractures. 108 Further research on the relationships between marrow fat and bone fragility in diabetes is needed to determine whether bone marrow fat has potential as a biomarker for fracture prediction.
Fracture consequences in T1D and T2D
For older patients in the general population, fractures can have serious consequences: in the year following a hip fracture, 50% of individuals are unable to live independently, 40% cannot walk, and 20% die; 109 mortality is increased for at least 5 years afterwards. 110 In diabetic patients, these consequences are more severe, with higher postfracture mortality as well as a greater risk of postfracture complications. For T1D patients, the risk of inhospital short-term mortality was doubled during a fracture admission. 111 Longer term mortality following a hip fracture is also 1.44 times greater in a patient with diabetes (T1D or T2D) 112 and persists for at least 1 year. 113 Patients with diabetes are also at greater risk of in-hospital complications during a fracture admission, including increased risk of septicemia, deep would infections, and urinary tract infections.
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Bone and antidiabetes medications
TZDs, by activating PPAR-␥ , divert pluripotent mesenchymal cells to differentiate into the adipogenic rather than osteoblastic lineage, leading to bone loss. 114 A meta-analysis demonstrated that bone loss occurs in women on TZDs at the spine, femoral neck, and total hip. 115 The use of TZDs should thus be avoided in postmenopausal women with T2D at risk of fractures.
Sodium-glucose cotransporter 2 (SGLTs) inhibitors might also have adverse skeletal effects. An increased risk of fracture was reported in patients treated with canagliflozin within 3 months of beginning treatment. 116 It is unclear whether this is a class effect; fractures were not increased with empagliflozin. 117 The mechanism underlying the skeletal effect of SGLT2 inhibitors may be related to increases in serum phosphate and PTH levels, although further elucidation is required. 118 There do not appear to be adverse skeletal effects of other diabetes medications; metformin, sulfonylureas, and incretin mimetics may have beneficial skeletal effects.
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Therapies for diabetic bone disease
Diabetic patients are less likely to receive osteoporosis treatment as compared with nondiabetic individuals, even if they have more risk factors such as increased age, prior fractures, or steroid use. 120, 121 In Denmark, 22% of diabetic patients versus 25% of nondiabetic patients were treated for osteoporosis; 120 similarly, in Canada 17% of diabetic versus 28% of nondiabetic patients received osteoporosis treatment. 121 Improved glucose control has been investigated as an intervention for skeletal health. In the AC-CORD study, which compared conventional versus intensive glycemic control, tighter glycemic control (average HbA1c 7.5% in the conventional control group versus HbA1c 6.4% in the intensive group) did not affect the risk of fractures or falls. 122 Although this would seem to suggest that fracture risk is not reduced with improved glycemic control, several caveats apply. Specifically, the standard glycemic control group had relatively well-controlled HbA1c levels and other studies show that hip fracture risk increases only if HbA1c is greater than or equal to 8%. 13, 14 It might also be hard to extrapolate from ACCORD regarding delayed effects of glycemic control on fractures because the study duration was only 4 years. Importantly, fracture risk in T1D and T2D increases with hypoglycemia, conceivably due to falls. 123, 124 Thus the importance of glycemic control must be weighed against potential harmful effects of hypoglycemia.
The rationale for therapy with antiresorptive agents in diabetes patients might seem questionable because such drugs would suppress bone remodeling beyond the low levels already present with diabetes. However, BMD in diabetic patients, even though it underestimates fracture risk, still predicts fracture risk, suggesting that increasing BMD levels in diabetics via anti resorptive therapies could be effective in preventing fractures. 25 Moreover, in glucocorticoid-induced osteoporosis, another disease demonstrating reduced bone formation, bisphosphonates are effective in preventing fractures. A number of lines of evidence support the efficacy of antiresorptive agents in diabetes. A post hoc analysis of the Fracture Intervention Trial (FIT) showed that alendronate increased BMD at the spine and hip in women with diabetes equally to nondiabetic women. 125 In women with diabetes, raloxifene reduced the risk of vertebral fractures to a similar extent as in women without diabetes in the Raloxifene Use for the Heart (RUTH) study. 126 Similarly, no difference was detected in fracture rates in the Danish Registry database during treatment with bisphosphonates or raloxifene with diabetes (T1D or T2D) as compared with nondiabetic controls. 120 A preliminary post hoc analysis from FIT and HORI-ZON showed that in postmenopausal women with diabetes, alendronate and zoledronic acid preserved bone density and, as compared with placebo, reduced the risk of nonvertebral and morphometric vertebral fractures, suggesting that the antifracture efficacy of these agents was not inferior in women with diabetes. 127 The skeletal effectiveness of PTH or denosumab in diabetic patients is not known.
Of note, a rare side effect of osteoporosis treatment, osteonecrosis of the jaw, may be more likely to occur in patients with diabetes who are receiving bisphosphonates or denosumab. 128 Whether diabetes increases the risk for atypical femoral fractures, a rare potential complication of longstanding antiresorptive treatment, is uncertain because the data are conflicting.
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Conclusions
Fracture risk is heightened in patients with T1D and T2D. Poor glycemic control and longer duration of diabetes undoubtedly contribute to this risk, yet the pathophysiological chain of events leading to bone fragility is still being unraveled. Poor glycemic control is likely the inciting insult, leading to accumulation of AGEs and microvascular changes. This, in turn, probably leads to an impairment of bone formation, which, because of coupling with bone resorption, likely results in reduced bone turnover. This may then prolong the life span of type 1 collagen, which then might become damaged by further accumulation of AGEs. Eventually the resultant impairment in material properties most likely leads to increased fracture risk. Further research will require confirmation of these hypotheses. Notably, the significance of increased cortical porosity, particularly in the seemingly paradoxical setting of low bone turnover, is unclear.
In conclusion, skeletal deterioration should be understood as another diabetic complication, akin to retinopathy or nephropathy. Further investigation is needed to understand the issue of greater bone fragility in diabetes and how to protect this population as they age.
